NCT05858645

Correction of Psoriatic T Cell Signatures by Deucravacitinib

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: University of California, San Francisco · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

Detailed description

This is a one-arm, open-label study to examine the effect of deucravacitinib on cutaneous and blood immune cells of psoriatic patients. 25 subjects with moderate to severe psoriasis will be enrolled. Biopsy and blood samples will be collected before and during treatment and undergo molecular profiling to assess for deucravacitinib-corrected signatures.

Conditions

• Psoriasis Vulgaris

Interventions

Type	Name	Description
DRUG	deucravacitinib	Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment

Timeline

• Start date: 2023-10-01
• Primary completion: 2026-06-01
• Completion: 2026-06-01
• First posted: 2023-05-15
• Last updated: 2024-06-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study